Quick Answer
BIOCRYST PHARMACEUTICALS INC reported Stockholders Equity of -$119.15 million for the year ending 2025.
- BIOCRYST PHARMACEUTICALS INC showed an increase of +75.0% in Stockholders Equity from 2024 to 2025.
- This data is from BIOCRYST PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$5.72 million | Q2 2014: $90.09 million | Q3 2014: $83.45 million | Q1 2015: $64.37 million | Q2 2015: $76.09 million | Q3 2015: $64.05 million | Q1 2016: $27.80 million | Q2 2016: $13.39 million | Q3 2016: $3.99 million | Q1 2017: $38.53 million | Q2 2017: $24.08 million | Q3 2017: $100.63 million | Q1 2018: $62.05 million | Q2 2018: $46.18 million | Q3 2018: $72.87 million | Q1 2019: $22.51 million | Q2 2019: -$9.19 million | Q3 2019: -$41.25 million | Q1 2020: $3.65 million | Q2 2020: $76.51 million | Q3 2020: $33.64 million | Q1 2021: -$74.99 million | Q2 2021: -$106.08 million | Q3 2021: -$147.04 million | Q1 2022: -$164.22 million | Q2 2022: -$213.23 million | Q3 2022: -$242.66 million | Q1 2023: -$328.29 million | Q2 2023: -$388.71 million | Q3 2023: -$410.99 million | Q1 2024: -$476.17 million | Q2 2024: -$475.61 million | Q3 2024: -$468.56 million | Q1 2025: -$451.93 million | Q2 2025: -$421.59 million | Q3 2025: -$387.89 million.
- Over the full 14 years of available data (2012 to 2025), BIOCRYST PHARMACEUTICALS INC's Stockholders Equity has declined by 26,145.2%.
- Historical annual values: Fiscal year 2025: -$119.15 million | Fiscal year 2024: -$475.93 million | Fiscal year 2023: -$455.53 million | Fiscal year 2022: -$294.60 million | Fiscal year 2021: -$106.99 million | Fiscal year 2020: -$19.26 million | Fiscal year 2019: $38.25 million | Fiscal year 2018: $49.24 million | Fiscal year 2017: $83.77 million | Fiscal year 2016: $1.58 million | Fiscal year 2015: $47.72 million | Fiscal year 2014: $75.64 million | Fiscal year 2013: -$1.13 million | Fiscal year 2012: -$454.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: